• Home
  • TOPICS
  • ImmuniT Research Inc. has entered into a non-exclusive license agreement with Boehringer Ingelheim of Germany for novel biomarkers for the treatment of cancer.

ImmuniT Research Inc. has entered into a non-exclusive license agreement with Boehringer Ingelheim of Germany for novel biomarkers for the treatment of cancer.January 28, 2022

ImmuniT Research Inc. announced today that it has entered into a non-exclusive license agreement with Boehringer Ingelheim of Germany for novel biomarkers for the treatment of cancer.

ImmuniT Research Inc. has entered into a non-exclusive license agreement with Boehringer Ingelheim of Germany for novel biomarkers for the treatment of cancer.